{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:04:21Z","timestamp":1769515461492,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Tianjin Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["19JCZDJC32900"],"award-info":[{"award-number":["19JCZDJC32900"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Program","doi-asserted-by":"publisher","award":["20YFZCSY00060"],"award-info":[{"award-number":["20YFZCSY00060"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111232","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T03:17:37Z","timestamp":1702437457000},"page":"111232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients"],"prefix":"10.1016","volume":"127","author":[{"given":"Hong","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-4169","authenticated-orcid":false,"given":"Chaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9928-9224","authenticated-orcid":false,"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2023.111232_b0005","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2023.111232_b0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.intimp.2023.111232_b0015","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.intimp.2023.111232_b0020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111232_b0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2023.111232_b0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.111232_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"20","key":"10.1016\/j.intimp.2023.111232_b0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2023.111232_b0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr. (Engl. Ed.)"},{"issue":"12","key":"10.1016\/j.intimp.2023.111232_b0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European Leukemia Net MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2023.111232_b0055","first-page":"141","article-title":"High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"49","author":"T\u00f3thov\u00e1","year":"2002","journal-title":"Neoplasma"},{"issue":"3","key":"10.1016\/j.intimp.2023.111232_b0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.intimp.2023.111232_b0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.14684","article-title":"Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment","volume":"178","author":"Vogler","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111232_b0070","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.intimp.2023.111232_b0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.htct.2018.09.001","article-title":"Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia","volume":"41","author":"EDVC","year":"2019","journal-title":"Hematol. Transfus. Cell Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.111232_b0080","first-page":"145","article-title":"Venetoclax-based therapies for acute myeloid leukemia. Best Practice & Research","volume":"32","author":"Guerra","year":"2019","journal-title":"Clin. Haematol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111232_b0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","article-title":"Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax","volume":"99","author":"Wang","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2023.111232_b0090","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy","volume":"10","author":"Richard-Carpentier","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"30","key":"10.1016\/j.intimp.2023.111232_b0095","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111232_b0100","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1097\/HS9.0000000000000549","article-title":"Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed\/Refractory Advanced Myeloid Malignancies","volume":"5","author":"Feld","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.intimp.2023.111232_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of Adults With Relapsed\/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2023.111232_b0110","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/10428194.2020.1867724","article-title":"Venetoclax and azacitidine(VenAZA)combination therapy in young unfit patients with AML: a perspective from a developing country","volume":"62","author":"Senapati","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"03","key":"10.1016\/j.intimp.2023.111232_b0115","first-page":"178","article-title":"Clinical observation of combination therapy of azacitidine and venetoclax in newly diagnosed, elderly patients with acute myeloid leukemia","volume":"16","author":"Huang","year":"2021","journal-title":"J. Intern. Med. Concepts Pract."},{"issue":"2","key":"10.1016\/j.intimp.2023.111232_b0120","first-page":"134","article-title":"Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience","volume":"43","author":"Yu","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692301559X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692301559X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:15:59Z","timestamp":1761588959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692301559X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"alternative-id":["S156757692301559X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111232","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111232"}}